Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-08-12

Clinical Trial Update: Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696) [Phase 4]

View source ↗

Summary

Phase 4 trial update identifying predictive factors for ovarian stimulation with a fixed daily dose of 200 IU recombinant FSH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • recombinant FSH (follicle-stimulating hormone)

Snippet

Sponsor: Organon and Co | Conditions: Infertility | Phase 4 | Status: COMPLETED | Results posted: 2009-08-12